This assay detects at least 36 previously described mutations in exons 18, 19, 20 and 21 of the epidermal growth factor receptor (EGFR) gene. The presence of some of these mutations correlates with better prognosis and better response to certain EGFR inhibitor cancer therapies in non-small cell lung carcinoma (NSCLC) patients.
Paraffin embedded tissue block sent to the Histopathology Section. Alternatively, unstained slides can be sent to the Histopathology Section. Note : - At least 8 sections of 8 mm thickness, or 12 sections of 5 mm thickness for smaller biopsies should be sent together with one H&E slide, 4 mm thick with a coverslip as a reference slide. - Tumour content must be indicated and must be at least 30%.
Direct PCR sequencing (in-house test)
Specific mutations detected, No mutations Detected or Inconclusive
Monday and Wednesday
14 Jan 2013 05:15 PM
Updated Turnaround Time to within 10 days